Cargando…

Targeting immune checkpoints in malignant glioma

Malignant glioma is the most common and a highly aggressive cancer in the central nervous system (CNS). Cancer immunotherapy, strategies to boost the bodys anti-cancer immune responses instead of directly targeting tumor cells, recently achieved great success in treating several human solid tumors....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xuhao, Zhu, Shan, Li, Tete, Liu, Yong-Jun, Chen, Wei, Chen, Jingtao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351697/ https://www.ncbi.nlm.nih.gov/pubmed/27756892 http://dx.doi.org/10.18632/oncotarget.12702

Ejemplares similares

T lymphocyte-targeted immune checkpoint modulation in glioma
por: Kelly, William James, et al.
Publicado: (2020)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes
por: Qi, Yangzhi, et al.
Publicado: (2020)

SYK Is Associated With Malignant Phenotype and Immune Checkpoints in Diffuse Glioma
por: Zhou, Quanwei, et al.
Publicado: (2022)

Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma
por: Deng, Shuanglin, et al.
Publicado: (2014)

Critical Roles of Balanced Innate Lymphoid Cell Subsets in Intestinal Homeostasis, Chronic Inflammation, and Cancer
por: Wu, Jing, et al.
Publicado: (2019)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives
por: Lin, Ningjing, et al.
Publicado: (2020)

Correction: T lymphocyte-targeted immune checkpoint modulation in glioma
Publicado: (2020)

Identification of Potential Immune Checkpoint Inhibitor Targets in Gliomas via Bioinformatic Analyses
por: Ding, Mengmeng, et al.
Publicado: (2022)

GDF15 promotes glioma stem cell-like phenotype via regulation of ERK1/2–c-Fos–LIF signaling
por: Zhu, Shan, et al.
Publicado: (2021)

miR-138 exerts anti-glioma efficacy by targeting immune checkpoints
por: Wei, Jun, et al.
Publicado: (2013)

Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
por: Mazloom, Anita, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
por: DeCarli, Kathryn, et al.
Publicado: (2022)

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
por: Wang, Hao, et al.
Publicado: (2019)

Treatment of malignant glioma using hyperthermia
por: Sun, Jiahang, et al.
Publicado: (2013)

Targeted therapy in the treatment of malignant gliomas
por: Lukas, Rimas V, et al.
Publicado: (2009)

Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood
por: Shen, Shaoping, et al.
Publicado: (2021)

Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis
por: Mansorunov, Danzan, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment
por: Xu, Tao, et al.
Publicado: (2018)

A Novel Immune-Related Prognostic Biomarker and Target Associated With Malignant Progression of Glioma
por: Zhang, Yu, et al.
Publicado: (2021)

Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
por: Li, Jun-Yan, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
por: Ghouzlani, Amina, et al.
Publicado: (2021)

Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
por: Liu, Ziyu, et al.
Publicado: (2019)

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
por: Chao, Mark P., et al.
Publicado: (2020)

Targeting FGL2 in glioma immunosuppression and malignant progression
por: Ma, Xiaoyu, et al.
Publicado: (2022)

Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
por: Ho, Rachel L. Y., et al.
Publicado: (2021)

Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy
por: Li, Guan-Zhang, et al.
Publicado: (2019)

Immune checkpoint: The novel target for antitumor therapy
por: Jiang, Xianghu, et al.
Publicado: (2019)

Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy
por: Zhou, Xianyong, et al.
Publicado: (2023)

Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade
por: Dmello, Crismita, et al.
Publicado: (2023)

The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
por: Borgeaud, Maxime, et al.
Publicado: (2023)

Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect
por: Du, Yang, et al.
Publicado: (2018)

Molecular biomarker‐guided anti‐angiogenic targeted therapy for malignant glioma
por: Yan, Chengrui, et al.
Publicado: (2019)

Immune Checkpoints: Therapeutic Targets for Pituitary Tumors
por: Nie, Ding, et al.
Publicado: (2021)

Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways
por: Liu, Jiaxin, et al.
Publicado: (2021)

Targeting the Complement Pathway in Malignant Glioma Microenvironments
por: Zhu, Hongtao, et al.
Publicado: (2021)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas()
por: Wang, Hongxiang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ea362ehj935rrcso7538khee1r